Skip to main content

Treatment Clinical Trials for Melanoma

Review the melanoma treatment clinical trials on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 76-100 of 176

Stereotactic Body Radiation Therapy with Nivolumab and BMS986253 for the Treatment of Multiple Metastases in Patients with Advanced Solid Tumors
Status: Active
Location: 2 locations
A Study of NTX-1088, a Monoclonal Antibody Targeting the Poliovirus Receptor (PVR, CD155), as Monotherapy and Combined With Pembrolizumab
Status: Active
Location: 2 locations
Neoadjuvant Darovasertib in Primary Uveal Melanoma
Status: Active
Location: 5 locations
Comparison of In-Home versus In-Clinic Administration of Subcutaneous Nivolumab through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program
Status: Active
Location: Mayo Clinic in Florida, Jacksonville, Florida
Comparing Length of Treatment with Immunotherapy in Patients with Advanced Solid Tumors
Status: Active
Location: University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania
Immunotherapy and Cryoablation of an Enlarging Tumor for the Treatment of Unresectable Metastatic Melanoma
Status: Active
Location: Massachusetts General Hospital Cancer Center, Boston, Massachusetts
Binimetinib and Encorafenib for the Treatment of Metastatic Melanoma and Central Nervous System Metastases
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Cyclophosphamide with Pembrolizumab in Treating Checkpoint Inhibitor Refractory Stage III or IV Melanoma
Status: Active
Location: UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange, California
Zimberelimab and Domvanalimab for the Treatment of Relapsed or Refractory Melanoma
Status: Active
Location: University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania
Tebentafusp for the Treatment of HLA-A*0201 Positive, Metastatic Uveal Melanoma with Integrated Circulating Tumor DNA Biomarker, TARGET-tebe Trial
Status: Active
Location: University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania
Cyclophosphamide, Fludarabine, Tumor Infiltrating Lymphocytes, and Aldesleukin in Treating Patients with Metastatic Uveal Melanoma
Status: Active
Location: University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania
Olaparib in Combination with Pembrolizumab for the Treatment of Metastatic Uveal Melanoma
Status: Active
Location: Moffitt Cancer Center, Tampa, Florida
Study of the Efficacy of Intratumoral L19IL2 or L19TNF or L19IL2/L19TNF, in Combination with Pembrolizumab, in Unresectable Melanoma Patients
Status: Active
Location: Memorial Sloan Kettering Cancer Center, New York, New York
Axitinib and Ipilimumab for the Treatment of Advanced Melanoma
Status: Active
Location: Moffitt Cancer Center, Tampa, Florida
A Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab
Status: Active
Location: National Institutes of Health Clinical Center, Bethesda, Maryland
Nivolumab in Combination with Relatlimab in Treating Patients with Active Melanoma Brain Metastases
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
High-Dose Interleukin-2, Ipilimumab and Nivolumab for the Treatment of Patients with Stage III-IV Melanoma
Status: Active
Location: Moffitt Cancer Center, Tampa, Florida
Melphalan via Percutaneous Hepatic Perfusion followed by Tebentafusp for the Treatment of Uveal Melanoma Metastatic to the Liver
Status: Active
Location: Moffitt Cancer Center, Tampa, Florida
Neoadjuvant Anti-PD-L1 Immunotherapy for the Treatment of Advanced Melanoma
Status: Active
Location: Moffitt Cancer Center, Tampa, Florida
Relatlimab, Nivolumab, and Ipilimumab for the Treatment of Unresectable or Metastatic Melanoma with Asymptomatic or Symptomatic Brain Metastases
Status: Active
Location: Stanford Cancer Institute Palo Alto, Palo Alto, California
Ipilimumab and Nivolumab before Surgery for the Treatment of Recurrent, High Risk, Resectable Stage IIIB-IV Metastatic Melanoma (NeoRelapse)
Status: Active
Location: Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah
Time-of-Day Specified Ipilimumab and Nivolumab for the Treatment of Stage IV Unresectable Melanoma, The TIME Trial
Status: Active
Location: 2 locations
A Research Study to Evaluate Tebentafusp before Surgery or Radiation for Certain Patients with Large Uveal Melanoma
Status: Active
Location: Thomas Jefferson University Hospital, Philadelphia, Pennsylvania
Nivolumab plus Axitinib for the Treatment of Stage III or IV Melanoma
Status: Active
Location: University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania
Phase II Trial of Combination Anti-PD-1 and Aldesleukin for Metastatic Melanoma and Renal Cell Carcinoma
Status: Active
Location: National Institutes of Health Clinical Center, Bethesda, Maryland